| Identification | Back Directory | [Name]
USP25 and 28 inhibitor AZ-1 | [CAS]
2165322-94-9 | [Synonyms]
AZ-1;AZ 1;AZ1
USP25/28 inhibitor AZ1
USP25 and 28 inhibitor AZ-1
Ethanol, 2-[[[5-bromo-2-[[4-fluoro-3-(trifluoromethyl)phenyl]methoxy]phenyl]methyl]amino]- | [Molecular Formula]
C17H16BrF4NO2 | [MDL Number]
MFCD32201047 | [MOL File]
2165322-94-9.mol | [Molecular Weight]
422.21 |
| Chemical Properties | Back Directory | [Boiling point ]
478.5±40.0 °C(Predicted) | [density ]
1.488±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: ≥ 250 mg/mL (592.12 mM); Water: < 0.1 mg/mL (insoluble) | [form ]
Solid | [pka]
14.74±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
USP25/28 inhibitor AZ1 (AZ1) is an orally active, selective, noncompetitive, dual ubiquitin specific protease (USP) 25/28 inhibitor with IC50s of 0.7 μM and 0.6 μM, respectively. USP25/28 inhibitor AZ1 attenuates colitis and tumorigenesis in the mice model[1][2]. | [Biological Activity]
AZ1 is a potent and selective dual USP25 & USP28 deubiquitinase (DUBs) inhibitor (USP25/28 IC50 = 0.62/0.7 nM by Ub-Rh110 assay) th at induces HCT116 cellular c-Myc degradation (20-100 μM for 3h or 60 μM for 0.3-3h). AZ1 exhibits antiproliferation activity in cancer cultures (IC50 ≤20 μM; HCT116HT29 and SW480) and anti-tumor efficacy in an orthotopic model of lung SCC tumours in mice in vivo (125 mg/kg or 375 mg/kg i.p. once every three days6 injections total). | [in vivo]
USP25/28 inhibitor AZ1 (AZ1; 40?mg/kg; gavage; daily; for 7?days) protects from dextran sulfate sodium (DSS)-induced weight loss and diarrhea and impaired colon shortening[1].
USP25/28 inhibitor AZ1 (20?mg/kg/day; gavage; 6 times a week in the 1, 3, 6 weeks) treatment significantly reduces tumor numbers in colons. Expression of Wnt-related genes and levels of pSTAT3 are decreased and levels of SOCS3 are increased in tumors. AZ1 gavage does not alleviate DSS-induced colitis in Usp25-/- mice or the spontaneous colitis of Il10-/- mice[1].
USP25/28 inhibitor AZ1 (20?mg/kg/day; gavage; every 3?days from 13-20 weeks) significantly inhibits tumorigenesis in the colon and prolonged the survival of AOM/Vil-Cre;Trp53fl/fl (VP) mice. AZ1 treatment has minimal effect on tumorigenesis in the USP25-deficient background[1].
| Animal Model: | 12-week old male Usp25+/+ and Usp25-/- mice[1] | | Dosage: | 40?mg/kg | | Administration: | Gavage; daily; for 7?days | | Result: | Protected from dextran sulfate sodium (DSS)-induced weight loss and diarrhea and impaired colon shortening and potentiated the expression of proinflammatory cytokines and antibacterial peptides in colons of Usp25-/- mice compared to control counterparts.
|
| [References]
[1] Wrigley JD, et al. Identification and Characterization of Dual Inhibitors of the USP25/28 Deubiquitinating EnzymeSubfamily. ACS Chem Biol. 2017 Dec 15;12(12):3113-3125. DOI:10.1021/acschembio.7b00334
[2] Xiao-Meng Wang, et al. The deubiquitinase USP25 supports colonic inflammation and bacterial infection and promotes colorectal cancer. Nature Cancer volume 1, pages811–825(2020). |
|
| Company Name: |
InvivoChem Gold
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|